Evidence map›Paper›PMID 40542278›Full record

ReviewClinical reviews in allergy & immunology2025

Aberrant Activation of Mast Cells: Molecular Mechanisms and Targets for Intervention.

Jinghao Wen, Zehao Lan, Liting He, Hai Long

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Drug allergy history predicts early progression-free survival benefit from PD-(L)1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jinghao WenDepartment of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Zehao LanDepartment of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Liting HeDepartment of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. heliting@csu.edu.cn.
Hai LongDepartment of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. dr.hailong@csu.edu.cn.ORCID http://orcid.org/0000-0001-6135-1486

Funding

National Key Research and Development Program of China No. 2023YFC2509003National Natural Science Foundation of China No. 82273540Science and Technology Innovation Program of Hunan Province No. 2023RC1031
6 · The paper itself

Abstract

Mast cells play a key role in innate immunity by mediating host defense and maintaining tissue balance. They achieve this through the controlled release of bioactive mediators such as histamine, heparin, leukotrienes, and prostaglandin D2. Their functional diversity is enabled by multiple receptor systems that coordinate differentiation, maturation, and degranulation processes through tissue-specific microenvironmental signals. Pathological activation through allergen exposure or intrinsic regulatory dysfunction contributes to various disorders, ranging from allergic conditions to autoimmune diseases and chronic inflammatory states. Current anti-mast cell therapies have expanded from broad-spectrum antihistamines to more precise treatments targeting IgE or its surface receptors expressed on mast cells. Emerging insights into activation mechanisms of mast cells, particularly structural and functional characterization of critical receptors, have accelerated the development of novel therapeutic interventions. This review discusses the advances in molecular mechanisms of mast cell activation and summarizes how these findings redefine our understanding of disease progression and emerging therapeutic targets.

Indexed as

HypersensitivityMast CellsAnimalsCell DegranulationHumansImmunity, InnateMolecular Targeted TherapySignal TransductionAllergyAutoimmuneMast cellMolecular mechanismSignaling pathwayTherapeutic target

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.